Tags

Type your tag names separated by a space and hit enter

Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.
Euro Surveill. 2019 Jan; 24(3)ES

Abstract

The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one-cycle infection assay. Analysis of PA sequences of 6,891 influenza A and B viruses collected during 2016/17 and 2017/18 seasons showed amino acid substitutions: I38L (two A(H1N1)pdm09 viruses), E23G (two A(H1N1)pdm09 viruses) and I38M (one A(H3N2) virus); conferring 4-10-fold reduced susceptibility to baloxavir.

Links

PMC Free PDF

Authors+Show Affiliations

Gubareva LV
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.
Mishin VP
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.
Patel MC
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America. Battelle Memorial Institute, Atlanta, United States of America.
Chesnokov A
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.
Nguyen HT
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America. Battelle Memorial Institute, Atlanta, United States of America.
De La Cruz J
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America. Battelle Memorial Institute, Atlanta, United States of America.
Spencer S
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.
Campbell AP
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.
Sinner M
Illinois Department of Public Health, Springfield, United States of America.
Reid H
Illinois Department of Public Health, Springfield, United States of America.
Garten R
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.
Katz JM
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.
Fry AM
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.
Barnes J
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.
Wentworth DE
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.

MeSH

Amino Acid SubstitutionAntiviral AgentsDibenzothiepinsDrug Resistance, ViralEnzyme InhibitorsHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza B virusInfluenza, HumanMicrobial Sensitivity TestsMorpholinesOxazinesPyridinesPyridonesSeasonsSentinel SurveillanceThiepinsTriazinesUnited StatesViral Proteins

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30670144

Citation

Gubareva, Larisa V., et al. "Assessing Baloxavir Susceptibility of Influenza Viruses Circulating in the United States During the 2016/17 and 2017/18 Seasons." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 24, no. 3, 2019.
Gubareva LV, Mishin VP, Patel MC, et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill. 2019;24(3).
Gubareva, L. V., Mishin, V. P., Patel, M. C., Chesnokov, A., Nguyen, H. T., De La Cruz, J., Spencer, S., Campbell, A. P., Sinner, M., Reid, H., Garten, R., Katz, J. M., Fry, A. M., Barnes, J., & Wentworth, D. E. (2019). Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 24(3). https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800666
Gubareva LV, et al. Assessing Baloxavir Susceptibility of Influenza Viruses Circulating in the United States During the 2016/17 and 2017/18 Seasons. Euro Surveill. 2019;24(3) PubMed PMID: 30670144.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. AU - Gubareva,Larisa V, AU - Mishin,Vasiliy P, AU - Patel,Mira C, AU - Chesnokov,Anton, AU - Nguyen,Ha T, AU - De La Cruz,Juan, AU - Spencer,Sarah, AU - Campbell,Angela P, AU - Sinner,Mallory, AU - Reid,Heather, AU - Garten,Rebecca, AU - Katz,Jackie M, AU - Fry,Alicia M, AU - Barnes,John, AU - Wentworth,David E, PY - 2019/1/24/entrez PY - 2019/1/24/pubmed PY - 2020/7/10/medline KW - Cap-dependent endonuclease inhibitor KW - drug resistance KW - influenza KW - influenza surveillance KW - next generation sequencing KW - phenotypic testing KW - polymerase acidic protein JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill VL - 24 IS - 3 N2 - The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one-cycle infection assay. Analysis of PA sequences of 6,891 influenza A and B viruses collected during 2016/17 and 2017/18 seasons showed amino acid substitutions: I38L (two A(H1N1)pdm09 viruses), E23G (two A(H1N1)pdm09 viruses) and I38M (one A(H3N2) virus); conferring 4-10-fold reduced susceptibility to baloxavir. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/30670144/Assessing_baloxavir_susceptibility_of_influenza_viruses_circulating_in_the_United_States_during_the_2016/17_and_2017/18_seasons_ DB - PRIME DP - Unbound Medicine ER -